Nicox Glaucoma Drug Effective in Late-Stage Studies

French pharmaceutical firm Nicox unveiled positive topline Phase 3 results for its glaucoma drug and said, if approved by regulators, the product could reach peak annual sales of over $1 billion worldwide.
Reuters Health Information

Full Story →